ADAI News & Events
July 2, 2026
Sen. Maria Cantwell (D-WA) Announces New Integrated Behavioral Health Center Modeled After Work of ADAI’s Caleb Banta-Green, PhD
U.S. Senator Maria Cantwell (D-WA) joined community leaders in Spokane, WA, this week for a ceremonial groundbreaking of a new integrated behavioral health center being spearheaded by Frontier Behavioral Health (FBH) and the Community Health Association of Spokane (CHAS Health). Sen. Cantwell secured $2 million through the Health Resources and Services Administration (HRSA) to construct…
June 30, 2026
2026 ADAI Symposium on Cannabinoid Hyperemesis Syndrome (Sept. 18): Registration & Call for Poster Abstracts Open!
The Dose Makes the Poison: Cannabinoid Hyperemesis Syndrome Goes Mainstream September 18, 2026 | 9:00am – 4:00pm PT Attend virtually or in person at the UW Tower Auditorium. View program | Register | Submit abstract for a digital poster (due Aug 18) Cannabinoid Hyperemesis Syndrome (CHS) is becoming increasingly visible in clinical settings, but many providers are navigating diagnosis, treatment, and patient communication without clear guidance. In a recent survey of Washington…
June 18, 2026
ADAI’s Mary Hatch & Inga Manskopf Recognized by Department for Professional Excellence
We are proud to announce that two of our team were recently recognized by our department (UW Psychiatry & Behavioral Sciences) for their excellent work! ADAI Associate Professor Mary Hatch, PhD, was awarded the Wayne J. Katon Outstanding Research Mentor Award, which recognizes a faculty member who has demonstrated excellence in research mentoring of faculty…
June 17, 2026
CEDEER Handout: Cutting Back on Stimulants with Contingency Management
Contingency management (CM) is an evidence-based intervention that can help people quit or cut back on stimulants, including methamphetamine and cocaine. This one-page handout was created by the ADAI Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER) to help educate patients or clients about this treatment option. The handout includes information on: More information…
June 16, 2026
Congratulations to our Spring ADAI Small Grant Awardees!
What are ADAI Small Grants? ADAI works to stimulate and facilitate UW research on alcohol and drug use and addiction through its Small Grants Program, which awards funds to UW researchers for pilot studies and developmental research. The scope ranges from pharmacology of drugs to studies of clinical treatment strategies, prevention, and social policy issues….
June 15, 2026
New ADAI Report Explores Smoking Supply Use and Impacts in Washington State
From 2015 to 2025, Washington State saw a dramatic shift in opioid and stimulant use, with smoking replacing injecting as the primary route of administration among syringe services program clients. More than half of syringe services programs in the state now offer safer smoking supplies. Safer Smoking Supplies – Use, Engagement, and Association with Decreasing…
June 11, 2026
RECORDING AVAILABLE: Washington State Community Drug Checking Network (CDCN) – June 11, 1pm PT
Update: This event was held on June 11, 2026.The slides & recording are now available. The Washington State Community Drug Checking Network (CDCN) is a partnership of organizations that provide community-level drug checking (offering people who use drugs information about what’s in their drugs) and related harm reduction services. This webinar, presented in partnership with…
June 10, 2026
RECORDING AVAILABLE: ADAI/CEDEER Virtual Conference: Supporting the Health of People Who Use Drugs, June 2-3, 2026
ADAI’s Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER) met over two days to learn more about practical strategies and programs that support the health of people who use drugs in Washington State.The session recordings and slides are now available! Topics for this event included: Presentations from experts from WA DOH, Clallam County Public…
June 9, 2026
New ADAI Report: Syringe Services Program Participants’ Perceptions, Concerns, and Experiences of Medications for Opioid Use Disorder (MOUD)
Medications like methadone and buprenorphine can be a powerful tool for people with opioid use disorder, but access and experiences vary. This new ADAI report, written by Teresa Winstead, PhD, MA, and Alison Newman, MPH (both of the Center for Community-Engaged Drug Education, Epidemiology & Research) shares what 18 syringe services program participants said about…
June 2, 2026
ADAI Lunch & Learn: Increasing Resilience from Alcohol Harm: Gender-Affirming & Inclusive Healthcare (June 26, 12pm PT)
Join ADAI and presenter Jessica Canning, PhD, of the UW Center for the Study of Health and Risk Behaviors (CSHRB) and Seven Directions, for our next virtual Lunch & Learn session, June 26, 2026, 12-1pm PT! Transgender and nonbinary adults are disproportionately impacted by harm from alcohol use, and these disparities are compounded for trans…
Next page
